载脂蛋白E基因多态性与华法林维持剂量之间的关联。

Association between apolipoprotein E gene polymorphism and the dose for warfarin maintenance.

作者信息

Huang Shengwen, Chen Baolin, Xiang Daokang, Huang Ling, An Bangquan, Li Guifang

机构信息

Department of Laboratory Medicine, Guizhou Provincial People's Hospital, Guiyang 550002, China.

出版信息

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Mar;36(3):212-6. doi: 10.3969/j.issn.1672-7347.2011.03.004.

DOI:10.3969/j.issn.1672-7347.2011.03.004

PMID:21464541

Abstract

OBJECTIVE

To investigate the association between the apolipoprotein E (apoE) gene polymorphism and the dose for warfarin individual maintenance.

METHODS

The genotypes of 249 patients with warfarin treatment in maintenance doses were determined by PCR/DHPLC assay. The doses for warfarin maintenance were compared among patients with different genotypes.

RESULTS

In the total of 249 patients, the frequencies of 2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, ε4/ε4 genotype were 1.20%, 15.66%, 1.80%, 72.29%, 9.24%, 0.80%, respectively; the allele frequencies of ε2, ε3, ε4 were 9.44%, 84.74%, 5.82%, respectively. The warfarin dose of group ε2 (ε2/ε2, ε2/ε3) was (3.24 ± 1.36) mg/d, slightly higher than that of group ε3 (ε3/ε3, 2.91 ± 1.14 mg/d) or group ε4 [ε4/ε4, ε3/ε4, (2.98 ± 1.05) mg/d], but the difference of the warfarin doses among the 3 groups did not reach statistical significance (F=1.848,P>0.05).

CONCLUSION

ApoE polymorphism may be not a major genetic factor that influences the individual dose for warfarin maintenance.

摘要

目的

探讨载脂蛋白E（apoE）基因多态性与华法林个体维持剂量之间的关联。

方法

采用聚合酶链反应/变性高效液相色谱（PCR/DHPLC）分析法测定249例接受华法林维持剂量治疗患者的基因型。比较不同基因型患者的华法林维持剂量。

结果

249例患者中，ε2/ε2、ε2/ε3、ε2/ε4、ε3/ε3、ε3/ε4、ε4/ε4基因型的频率分别为1.20%、15.66%、1.80%、72.29%、9.24%、0.80%；ε2、ε3、ε4等位基因频率分别为9.44%、84.74%、5.82%。ε2组（ε2/ε2、ε2/ε3）的华法林剂量为（3.24±1.36）mg/d，略高于ε3组（ε3/ε3，2.91±1.14mg/d）或ε4组[ε4/ε4、ε3/ε4，（2.98±1.05）mg/d]，但三组间华法林剂量差异无统计学意义（F=1.848，P>0.05）。